credit / rates affecting interest expense
“These increases were partially offset by $1.1 million of increased interest expense related to our 2024 Credit Facility.”
TARS 10-K
7 names are moving together; 43% are participating in the current session.
Observed intraday paths are not available for this group yet.
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| TARS | Tarsus Pharmaceuticals, Inc. | Healthcare | -5.2% | Most structurally connected |
| TWO | Two Harbors Investment Corp | Real Estate | +0.2% | Group member |
| AZN | AstraZeneca PLC | Healthcare | -3.0% | Group member |
| ALHC | Alignment Healthcare, Inc. | Healthcare | +4.1% | Group member |
| BKD | Brookdale Senior Living Inc. | Healthcare | -1.6% | Group member |
| USFD | US Foods Holding Corp. | Consumer Defensive | -0.3% | Group member |
| SNDA | Sonida Senior Living, Inc. | Healthcare | -0.5% | Group member |
Cohort
7 namesParticipation
43% this sessionObserved history
1 daily buildsFiling coverage
6/7 memberscredit / rates affecting interest expense
“These increases were partially offset by $1.1 million of increased interest expense related to our 2024 Credit Facility.”
TARS 10-K
restructuring affecting expense
“The increase in net loss was primarily attributable to a $62.8 million increase in non-cash impairment charges, primarily related to the planned disposition of certain underperforming communities resulting in a change in their intended holding periods, the increase in facility operating expense, and a $32.8 million loss on extinguishment of a financing obligation during the year ended December 31, 2025 for the reacquisition of three communities previously subject to sale-leaseback transactions for the amount by which the repurchase price exceeded the previously recognized financing obligation for such three communities, partially offset by the increase in resident fees.”
BKD 10-K
credit / rates
“For example, the 2024 Credit Facility with Pharmakon, which provided, among other things, a $75.0 million initial term loan which was drawn in April 2024, restricts our ability to pursue certain transactions that we may believe to be in our best interests without the prior written consent of Pharmakon, including but not limited to: disposing of certain properties or assets, incurring additional indebtedness, granting liens, making 72 Table of Contents investments, paying dividends or making distributions or certain other restricted payments in respect of equity, prepaying other indebtedness, entering into restrictive agreements, undertaking fundamental changes or amending certain material contracts, in each case subject to certain customary exceptions and negotiated carve outs.”
TARS 10-Q
Senior Living Services can stay leader-led if BKD and the next software names fail to join while TARS keeps moving.
No high-confidence filing-linked non-members are available for this group yet.
Historical cohort observations are not available yet.